8 news items
Establishment Labs Reports First Quarter 2024 Financial Results
ESTA
8 May 24
an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support
Establishment Labs Notes Presentation Of 4-Year Results From Motiva U.S. IDE Study At The Aesthetic Meeting 2024
ESTA
2 May 24
of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic Meeting 2024 in Vancouver, BC
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
ESTA
2 May 24
augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results
Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America
ESTA
1 May 24
clinical investigation pursuant to U.S. FDA regulations for investigational medical devices
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8
ESTA
24 Apr 24
and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants®
194mmo nf5qqp8x2rt6n3p629s9bpm7tkulvotxlr
ESTA
17 Apr 24
.
At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update
64zkja5glfm5puq7x4by32qs5yh dflio0k27tbo
ESTA
1 Apr 24
.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how
njxerulnr nvzg
ESTA
28 Feb 24
:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva
- Prev
- 1
- Next